Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses.

Cancer GenetJul 1, 2026 (epub)
Clinical ResearchOncology (Medical)Radiology (Diagnostic)

Chengxin Liu, Guanghui Yang, Zhongtang Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized phase II trial evaluated the impact of simultaneous integrated boost (SIB) radiotherapy on progression-free survival (PFS) and overall survival (OS) in 168 patients with unresectable stage III non-small-cell lung cancer (NSCLC). The SIB group showed a median PFS of 21.0 months compared to 11.0 months in the control group (P < 0.001), and a median OS of 42.0 months versus 26.0 months (P = 0.002).

Key findings

  • Median PFS was 21.0 months in the SIB group vs 11.0 months in the control group (P < 0.001).
  • Median OS was 42.0 months in the SIB group vs 26.0 months in the control group (P = 0.002).
  • SIB group had a lower risk of brain metastasis with an adjusted HR of 0.35 (P = 0.025).
  • Lower radiation-related pneumonitis was observed in the SIB group (P = 0.015).

Why it matters

The findings suggest that SIB radiotherapy can significantly enhance survival outcomes in patients with stage III LA-NSCLC while minimizing radiation-related complications. This approach may inform treatment strategies in this patient population.

Source

PubMed · PMID 42456525

Published in Cancer Genet. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.